Key Highlights
- AEON Biopharma (NYSEAMERICAN:AEON) reported third-quarter Net Income of USD 2.5 million, or USD 0.01 per share, against a net loss of USD 4.5 million, or USD 0.39 per share, a year earlier.
- The profit came from a USD 7.0 million non-cash gain on Warrant fair values, while the loss from operations widened to USD 4.5 million from USD 2.5 million.
- Cash and cash equivalents were USD 11.4 million on September 30, 2026, against an accumulated Deficit of USD 481.3 million and a funding runway only into the second quarter of 2027.
- Stockholders' Equity of USD 2.4 million was below the USD 4.0 million NYSE American minimum at quarter end, before about USD 6.2 million of fourth-quarter warrant exercise proceeds.
A Warrant Gain Turns an Operating Loss Into Net Income
AEON Biopharma (NYSEAMERICAN:AEON) filed its Quarterly Report on November 16, 2026, for the period ended September 30. Third-quarter net income was USD 2.465 million versus a net loss of USD 4.538 million in the prior-year quarter. The swing came from a USD 7.014 million gain on the change in Fair Value of warrants, a non-cash item tied to the company's share price. Operating costs rose to USD 4.483 million from USD 2.493 million, with Research and Development up 154% to USD 1.5 million and selling, general and administrative expenses up 55% to USD 3.0 million. Weighted average shares outstanding reached 89,957,587, compared with 11,634,946 a year earlier.
What the Biosimilar Program Is Spending On
AEON develops ABP-450, a botulinum toxin complex it is positioning as a biosimilar to BOTOX for therapeutic uses, under rights from manufacturer Daewoong Pharmaceutical covering the United States, Canada, the European Union, the United Kingdom and other territories. The same complex is already marketed in the US for glabellar lines by Evolus under the Jeuveau brand. The company estimates the US therapeutic botulinum toxin market at about USD 3.5 billion in 2026, growing about 8% a year. A January 2026 FDA meeting reviewed its analytical similarity strategy under the 351(k) pathway. Nine-month research and development spending rose 161% to USD 6.5 million.
Going-Concern Doubt, Listing Standards and Funding
Management concluded there is substantial doubt about AEON Biopharma (NYSEAMERICAN:AEON) continuing as a going concern, because cash of USD 11.4 million is expected to fund operations only into the second quarter of 2027. July 2026 brought net proceeds of about USD 13.7 million from an offering and its over-allotment, and nine-month financing inflows totalled USD 20.5 million, while operating cash use was USD 12.1 million against USD 12.6 million a year earlier. NYSE American confirmed on August 3, 2026 that the company had regained compliance with its listing standards, yet equity of USD 2.4 million at quarter end was below the USD 4.0 million minimum. Warrant exercises with gross proceeds of about USD 6.2 million in the fourth quarter lifted equity above that level as of the filing date, though the exchange assesses compliance on reported statements.
Where Things Stand
The profit came from accounting, not from operations. AEON Biopharma (NYSEAMERICAN:AEON) earned USD 2.5 million in the third quarter because warrant liabilities fell in value by USD 7.0 million, while the core operating loss widened to USD 4.5 million. The nine-month net loss was USD 10.5 million versus USD 2.1 million. With cash of USD 11.4 million and a runway into the second quarter of 2027, the next markers are further financing, FDA correspondence on the analytical package and the next quarter's equity position against the NYSE American minimum.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...